Master surgery in 5 minutes a day

Get smart summaries of the latest surgical literature delivered daily. 5K+ surgical leaders already rely on Stitches to save time and stay ahead.

100% Free. No spam. Unsubscribe any time.

WHAT READERS SAY

As a consultant, my inbox is flooded with emails. But this one always makes the cut.

Sarah, Consultant (Germany)

The Daily Selection has completely changed my approach to reading surgical literature!

David, Trainee (UK)

An easy way to stay up to date in this fast paced field

N.E., Resident

How do you lead in the OR?
Every surgical team needs a leader — but leadership comes in many forms. Where do you fit in?

Take our quick quiz and discover your surgical leadership style in just 2 minutes.
It’s fun, fast, and scarily accurate.

👉 Want to dig deeper? Read our article on surgical leadership here.

Why STITCHES?

We make reading surgical science enjoyable and informative

SAVE TIME

STITCHES makes it easy by collecting all academic surgical papers and offering them to you in theme-based newsletters.

GET UNIQUE INSIGHTS

STITCHES is made by surgeons for surgeons, and we search every journal for the news and information you are looking for.

ENJOY STAYING INFORMED

We provide a 1) Daily Selection of the top 5 papers summarized daily, or subscribe to our 2) specialty newsletter for ALL articles in that field.

TOP STITCHES

  • Long-term Atezolizumab-Bevacizumab Outcomes in HCC
    Atezolizumab-bevacizumab shows promising long-term survival for patients with unresectable hepatocellular carcinoma. Median overall survival is 19.7 months with a 36-month survival rate of 30%. 36.8% experienced grade ≥3 adverse events; 14.1% had liver decompensation not related to tumor progression. Surgeons should consider multidisciplinary approaches, as 14.9% of patients underwent additional surgical or locoregional procedures post-treatment. Journal Article by Tovoli F, Iavarone M (…) Piscaglia F et 25 al. in Hepatology Copyright © 2026 American Association for the Study of Liver… Read more: Long-term Atezolizumab-Bevacizumab Outcomes in HCC

Get the Latest in Surgery!